Cancer Biology

Deciphering the CD73⁺ Regulatory γδ T Cell ecosystem associated with poor survival in Ovarian cancer

1. Ghita Chabab
2. Henri-Alexandre Michaud
3. Cécile Dejou
4. Laure-Agnès Chépeaux
5. Yaël Glasson
6. Florence Boissière
7. Marion Lenain
8. Anne-Sophie Dumé
9. Pauline Sarrant
10. Gabriel Chemin
11. Pauline Wajda
12. Bertrand Dubois
13. Anna MacManus
14. Pierre-Emmanuel Colombo
15. Michel Fabbro
16. Nathalie Bonnefoy
17. Maeva Chauvin
18. Virginie Lafont

Reviewed by Review Commons

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

1. Veera K. Ojala
2. Sini Ahonen
3. Sara Peltola
4. Aura Tuohisto‐Kokko
5. Olaya Esparta
6. Peppi Suominen
7. Anne Jokilammi
8. Iman Farahani
9. Deepankar Chakroborty
10. Nikol Dibus
11. Steffen Boettcher
12. Tomi T. Airenne
13. Mark S. Johnson
14. Lisa D. Eli
15. Klaus Elenius
16. Kari J. Kurppa

Reviewed by Review Commons

Tumoral CD24 tunes platelets binding and pro-metastatic functions

1. Vincent Mittelheisser
2. Cristina Liboni
3. Clarisse Mouriaux
4. Silvia Maria Grazia Trivigno
5. Louis Bochler
6. Maria Garcia-Leon
7. Annabel Larnicol
8. Laetitia Paulen
9. Tristan Stemmelen
10. Pierre Henri Mangin
11. Olivier Lefebvre
12. Jacky G. GOETZ

Reviewed by preLights

Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition

1. Laleh S Arabanian
2. Jenni Adamsson
3. Anke Unger
4. Raffaella Di Lucrezia
5. Tim Bergbrede
6. Arghavan Ashouri
7. Erik Larsson
8. Peter Nussbaumer
9. Bert M Klebl
10. Lars Palmqvist
11. Claes M Gustafsson

• Curated by eLife

  eLife Assessment

  This solid study assesses a mitochondrial polymerase inhibitor in combination with the BCL-2 inhibitor venetoclax, with the aim to increase the elimination of acute myeloid leukemia. It provides valuable findings of combinatorial efficacy using preclinical models in vitro and in vivo, confirming the overall importance of targeting oxidative phosphorylation to overcome venetoclax resistance in acute myeloid leukemia, and could be strengthened through mechanistic studies demonstrating on target effects and pharmacodynamic efficacy in vivo. The study is of interest to hematologists because it addresses a key biomedical issue in acute myeloid leukemia (venetoclax resistance) and provides data regarding the safety and activity of a novel inhibitor of the mitochondrial polymerase in combination with venetoclax.

Reviewed by eLife